The global antinuclear antibody test market is estimated to garner noteworthy revenue by growing at a CAGR of ~13% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the higher prevalence of autoimmune diseases and the growing number of reagent rental agreements across the globe. According to a report published by World Health Organization (WHO), in 2017, there were 9 million people suffering from type 1 diabetes, while 422 million people in the global population have some sort of diabetes. Moreover, in 2019, 1.5 million people die due to diabetes every year. Furthermore, rising awareness of the ANA test is also projected to propel the growth of the market over the forecast period. Data released by the National Library of Medicine (NLM) in 2020 showed that 587,357 ANA tests were conducted while 437,966 patients took ANA tests worldwide. In modern times, both technology and awareness of health are growing exponentially. Hence, all these factors are anticipated to hike the growth of the market during the forecast period.
Get more information on this report: Request Sample PDF
The market is segmented by technology into immunofluorescence and multiplex assay, and ELISA, out of which, the ELISA segment is anticipated to hold a notable share in the global antinuclear antibody test market during the forecast period on account of its utilization to monitor therapeutic drug level and growing ANA application in autoimmune diseases. Furthermore, the expanded form for ELISA is an enzyme-linked immunoassay and it is generally utilized to examine antibodies in the blood.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Regionally, the global antinuclear antibody test market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region is estimated to witness noteworthy growth over the forecast period on the back of the growing geriatric population and rising cases of autoimmune diseases. Based on the report provided by the American Autoimmune Related Diseases Association (AARDA), it was stated that over 100 types of autoimmune diseases are found in the region while 50 million Americans suffer from some sort of autoimmune disease. Furthermore, rising cases of arthritis in North America are also projected to hike the growth of the market over the forecast period. According to the report published by the Centers for Disease Control and Prevention, the number of arthritis patients is projected to reach 78 million adults over the forecast period.
Furthermore, the market is anticipated to grow rapidly in the Asia Pacific region during the forecast period. The growth of the market in the region can be attributed to similar factors that are increasing cases of autoimmune diseases, and increment in the geriatric population. Additionally, escalating government initiatives in the healthcare sector can also be the major growth factor of the market during the forecast period.
Get more information on this report: Request Sample PDF
The global antinuclear antibody test market is further classified on the basis of region as follows:
North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
Our in-depth analysis of the global antinuclear antibody test market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Rising prevalence of autoimmune diseases and the growing population across the globe are the major factors driving the growth of the antinuclear antibody test market.
The market is anticipated to attain a CAGR of ~13% over the forecast period, i.e., 2022 - 2031.
The major players in the market are F. Hoffmann-La Roche Ltd, ERBA Diagnostics, Inc., Zeus Scientific Inc., Trinity Biotech plc, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Immuno Concepts Inc, and Becton, Dickinson and Company.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, disease, technology, end-user, and by region.
The ELISA segment is anticipated to hold the largest market size in value over the forecast period and display significant growth opportunities.
Lack of skilled professionals and errors during the diagnosis process is estimated to hamper the market growth.
North America region will provide more business opportunities for the growth of the antinuclear antibody test market in the future on the back of growing geriatric population.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization